Covid-19

Research and Development

Aerosol formulation of Bivalent Human VH Domains against multiple SARS-Cov-2 Spike variants

A collaborative research project with the Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School.

SARS-CoV-2 spike receptor binding domain intranasal vaccine formulation

A collaborative research project with the Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School.

Mucosal vaccines against COVID-19: open collaboration

Novochizol™ allows to address the main challenge in developing the ultimate COVID-19 vaccine: finding the right combination of antigens to elicit sterilizing mucosal immunity, leading to virus eradication.

Novochizol TM-Losartan aerosol formulation preclinical safety

On March 19,2020 we conducted an urgent pre-clinical animal safety assessment by administering to a swine Losartan-N aerosol, delivering approximately 270 micrograms of active ingredient over a period of 30 minutes.